Business, energy, technology, markets and global industry news from Business News Today

pancreatic cancer

PharmaDeviceNews pancreatic cancer
Representative image of oncology researchers reviewing cancer scans and molecular data, reflecting Ranok Therapeutics’ RNK08954 Phase 1a results and the accelerating race to develop KRAS G12D targeted therapies for pancreatic cancer, lung cancer and other advanced solid tumours.
Pharma & Biotech

Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up

KRAS G12D was long seen as nearly untouchable. Ranok’s RNK08954 now has early clinical data, but the pivotal test is still ahead.

Read More
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.

Read More
Pharma & Biotech

How RenovoRx’s TAMP platform data could reshape intra-arterial drug delivery in pancreatic cancer

RenovoRx’s ASCO 2026 data highlights how targeted gemcitabine delivery could reshape pancreatic cancer treatment strategy. Read more.

Read More
Representative image: ClearNote Health’s Avantect pancreatic cancer blood test highlights the growing role of liquid biopsy and multi-analyte diagnostics in early pancreatic cancer detection ahead of ASCO 2026.
Medical Devices & Diagnostics

ClearNote Health targets early pancreatic cancer detection with multi-analyte blood test data

ClearNote Health will present Avantect pancreatic cancer test validation data at ASCO 2026. Find out what it could mean for early detection.

Read More
Pharma & Biotech

What Can-Fite BioPharma Ltd.’s Phase 2b pancreatic cancer strategy reveals about immunotherapy combination economics

Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.

Read More
Pharma & Biotech

What Actuate Therapeutics, Inc.’s oral formulation push means for pancreatic cancer drug development economics

Actuate Therapeutics, Inc. is advancing oral elraglusib after FDA IND clearance. Discover what this means for pancreatic cancer economics.

Read More
Representative image of a microneedle catheter concept for targeted intratumoral drug delivery in pancreatic cancer, reflecting Vector Science & Therapeutics’ early-stage research into localized oncology treatment platforms.
Medical Devices & Diagnostics

Can Vector Science’s microneedle catheter patent crack one of oncology’s hardest delivery problems?

Pancreatic cancer needs local precision. Vector Science is betting a catheter patent can move drug delivery closer to the tumor.

Read More
Pharma & Biotech

Is Can-Fite BioPharma Ltd. building a differentiated niche in late-line pancreatic cancer therapy

Is Can-Fite BioPharma Ltd. carving a niche in pancreatic cancer? Explore how namodenoson’s Phase 2a data could reshape late-line treatment strategies.

Read More
Pharma & Biotech

Can Annamycin bridge cytotoxic therapy and immunotherapy in pancreatic cancer?

Find out how Annamycin could bridge chemotherapy and immunotherapy in pancreatic cancer and what AACR 2026 data signals for future trials.

Read More
Pharma & Biotech

Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?

Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.

Read More